Lyra Therapeutics, Inc.
LYRA
Price:
$0.1749
Market Cap:
$11.45M
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its ...[Read more]
Industry
Biotechnology
IPO Date
2020-05-01
Stock Exchange
NASDAQ
Ticker
LYRA
PE Ratio
[-0.12]
ROE
[-178.68%]
Current Ratio
[3.64]
Dividend Yield
[0%]
Enterprise Value
[22.97M]
Dividend History
The ROE as of December 2024 (TTM) for Lyra Therapeutics, Inc. (LYRA) is -178.68%
According to Lyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -178.68%. This represents a change of 176.08% compared to the average of -64.72% of the last 4 quarters.
Lyra Therapeutics, Inc. (LYRA) Historical ROE (quarterly & annually)
How has LYRA ROE performed in the past?
The mean historical ROE of Lyra Therapeutics, Inc. over the last ten years is -84.28%. The current -178.68% ROE has changed 111.99% with respect to the historical average. Over the past ten years (40 quarters), LYRA's ROE was at its highest in in the March 2020 quarter at 3.34%. The ROE was at its lowest in in the June 2024 quarter at -155.38%.
Average
-84.28%
Median
-69.27%
Minimum
-219.61%
Maximum
5.63%
Lyra Therapeutics, Inc. (LYRA) ROE by Quarter and Year
Discovering the peaks and valleys of Lyra Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 317.61%
Maximum Annual ROE = 5.63%
Minimum Annual Increase = -4000.23%
Minimum Annual ROE = -219.61%
| Year | ROE | Change |
|---|---|---|
| 2023 | -70.10% | 2.40% |
| 2022 | -68.45% | -44.61% |
| 2021 | -123.59% | 317.61% |
| 2020 | -29.59% | -86.52% |
| 2019 | -219.61% | -4000.23% |
Lyra Therapeutics, Inc. (LYRA) Average ROE
How has LYRA ROE performed in the past?
The current ROE of Lyra Therapeutics, Inc. (LYRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-87.38%
5-year avg
-102.27%
10-year avg
-84.28%
Lyra Therapeutics, Inc. (LYRA) ROE vs. Peers
How is LYRA’s ROE compared to its peers?
Lyra Therapeutics, Inc.’s ROE is greater than CytomX Therapeutics, Inc. (-41.34%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Achilles Therapeutics plc (-54.57%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Instil Bio, Inc. (-37.44%), greater than NextCure, Inc. (-62.50%), less than Spero Therapeutics, Inc. (3.36%), greater than Nuvation Bio Inc. (-108.68%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Bolt Biotherapeutics, Inc. (-69.46%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Autolus Therapeutics plc (-63.65%),
| Company | ROE | Market cap |
|---|---|---|
| -41.34% | $85.30M | |
| -121.46% | $94.84M | |
| -54.57% | $40.33M | |
| -8.54% | $8.20M | |
| -37.44% | $141.74M | |
| -62.50% | $26.35M | |
| 3.36% | $50.31M | |
| -108.68% | $898.63M | |
| -26.54% | $691.16M | |
| -69.46% | $19.56M | |
| -22.40% | $1.28B | |
| -63.65% | $580.14M |
Build a custom stock screener for Lyra Therapeutics, Inc. (LYRA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Lyra Therapeutics, Inc. (LYRA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Lyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Lyra Therapeutics, Inc.'s ROE?
How is the ROE calculated for Lyra Therapeutics, Inc. (LYRA)?
What is the highest ROE for Lyra Therapeutics, Inc. (LYRA)?
What is the 3-year average ROE for Lyra Therapeutics, Inc. (LYRA)?
What is the 5-year average ROE for Lyra Therapeutics, Inc. (LYRA)?
How does the current ROE for Lyra Therapeutics, Inc. (LYRA) compare to its historical average?